European Archives of Oto-Rhino-Laryngology

, Volume 264, Issue 7, pp 815–821

Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells

  • Takeharu Kanazawa
  • Hiroshi Nishino
  • Masahiro Hasegawa
  • Yasushi Ohta
  • Yukiko Iino
  • Keiichi Ichimura
  • Yutaka Noda
Head and Neck

Abstract

Interleukin-6 (IL-6) is a multifunctional regulator of immune response and hematopoiesis. Recently, it has been reported that expression of IL-6 is correlated with prognosis in various cancer patients. In this study, we investigated whether the proliferation and invasion potential of head and neck squamous cell carcinomas (HNSCCs) were influenced by IL-6. All HNSCC cell lines, HEp-2, HSC-2, HSC-4, and SAS, were tested by reverse transcription-polymerase chain reaction (RT-PCR) and expressed the IL-6 receptor (IL-6R), and glycoprotein 130, which is responsible for signal transduction. HEp-2, HSC-2, and HSC-4 also produced IL-6. IL-6 inhibited the proliferation of HSC-2 and SAS, but the invasion potential of all the cell lines increased. Moreover, IL-6 down-regulated soluble IL-6R expression. Anti-IL-6R antibody abrogated the inhibited proliferation and increased invasion induced by IL-6. IL-6 stimulation also induced the extracellular regulated protein kinase 1/2 activation and increased vascular endothelial growth factor release. These results suggest that IL-6 can directly influence cell proliferation and the invasion potential as the first step of tumor metastasis.

Keywords

IL-6 Head and neck cancer Invasion and metastasis Proliferation 

References

  1. 1.
    Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I, Lee JH (2003) Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 63:4648–4655PubMedGoogle Scholar
  2. 2.
    Raccurt M, Tam SP, Lau P, Mertani HC, Lambert A, Garcia-Caballero T, Li H, Brown RJ, McGuckin MA, Morel G, Waters MJ (2003) Suppressor of cytokine signalling gene expression is elevated in breast carcinoma. Br J Cancer 89:524–532PubMedCrossRefGoogle Scholar
  3. 3.
    Kishimoto T (1989) The biology of interleukin-6. Blood 74:1–10PubMedGoogle Scholar
  4. 4.
    Muraguchi A, Kishimoto T, Miki Y, Kuritani T, Kaieda T, Yoshizaki K, Yamamura Y (1981) T cell-replacing factor- (TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J Immunol 127:412–416PubMedGoogle Scholar
  5. 5.
    Mizutani H, May LT, Sehgal PB, Kupper TS (1989) Synergistic interactions of IL-1 and IL-6 in T cell activation. Mitogen but not antigen receptor-induced proliferation of a cloned T helper cell line is enhanced by exogenous IL-6. J Immunol 143:896–901PubMedGoogle Scholar
  6. 6.
    Gallagher G, Stimson WH, Findlay J, al-Azzawi F (1990) Interleukin-6 enhances the induction of human lymphokine-activated killer cells. Cancer Immunol Immunother 31:49–52PubMedCrossRefGoogle Scholar
  7. 7.
    Angelo LS, Talpaz M, Kurzrock R (2002) Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res 62:932–940PubMedGoogle Scholar
  8. 8.
    Takizawa H, Ohtoshi T, Ohta K, Yamashita N, Hirohata S, Hirai K, Hiramatsu K, Ito K (1993) Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res 53:4175–4181PubMedGoogle Scholar
  9. 9.
    Asschert JG, Vellenga E, Ruiters MH, de Vries EG (1999) Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int J Cancer 82:244–249PubMedCrossRefGoogle Scholar
  10. 10.
    Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E (1993) Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 50:15–19PubMedCrossRefGoogle Scholar
  11. 11.
    Pries R, Thiel A, Brocks C, Wollenberg B (2006) Secretion of tumor-promoting and immune suppressive cytokines by cell lines of head and neck squamous cell carcinoma. In Vivo 20:45–48PubMedGoogle Scholar
  12. 12.
    Mann EA, Spiro JD, Chen LL, Kreutzer DL (1992) Cytokine expression by head and neck squamous cell carcinomas. Am J Surg 164:567–573PubMedCrossRefGoogle Scholar
  13. 13.
    Chakravarti N, Myers JN, Aggarwal BB (2006) Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer 119:1268–1275PubMedCrossRefGoogle Scholar
  14. 14.
    Woods KV, El-Naggar A, Clayman GL, Grimm EA (1998) Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. Cancer Res 58:3132–3141PubMedGoogle Scholar
  15. 15.
    Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS (2003) Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 63:2948–2956PubMedGoogle Scholar
  16. 16.
    Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, Philip T, Favrot M (1992) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52:3317–3322PubMedGoogle Scholar
  17. 17.
    Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher LL, Van Waes C (1999) Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5:1369–1379PubMedGoogle Scholar
  18. 18.
    Badache A, Hynes NE (2001) Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res 61:383–391PubMedGoogle Scholar
  19. 19.
    Paysant J, Blanque R, Vasse M, Soria C, Soria J, Gardner CR (2000) Factors influencing the effect of the soluble IL-6 receptor on IL-6 responses in HepG2 hepatocytes. Cytokine 12:774–779PubMedCrossRefGoogle Scholar
  20. 20.
    Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B (1995) Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 86:3123–3131PubMedGoogle Scholar
  21. 21.
    Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 6:583–588PubMedCrossRefGoogle Scholar
  22. 22.
    Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D Jr, Corey E (2003) Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97:1211–1216PubMedCrossRefGoogle Scholar
  23. 23.
    Wellby ML, Kennedy JA, Pile K, True BS, Barreau P (2001) Serum interleukin-6 and thyroid hormones in rheumatoid arthritis. Metabolism 50:463–467PubMedCrossRefGoogle Scholar
  24. 24.
    Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, Thijs LG, Aarden LA (1989) Increased plasma levels of interleukin-6 in sepsis. Blood 74:1704–1710PubMedGoogle Scholar
  25. 25.
    Nishino H, Miyata M, Kitamura K (1998) The effect of interleukin-6 on enhancing the invasiveness of head and neck cancer cells in vitro. Eur Arch Otorhinolaryngol 255:468–472PubMedCrossRefGoogle Scholar
  26. 26.
    Yoshizaki K, Nishimoto N, Matsumoto K, Tagoh H, Taga T, Deguchi Y, Kuritani T, Hirano T, Hashimoto K, Okada N, Kishimoto T (1990) Interleukin 6 and expression of its receptor on epidermal keratinocytes. Cytokine 2:381–387PubMedCrossRefGoogle Scholar
  27. 27.
    Jourdan M, Veyrune JL, Vos JD, Redal N, Couderc G, Klein B (2003) A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 22:2950–2959PubMedCrossRefGoogle Scholar
  28. 28.
    Okamoto M, Lee C, Oyasu R (1997) Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57:141–146PubMedGoogle Scholar
  29. 29.
    Mihara M, Moriya Y, Ohsugi Y (1996) IL-6-soluble IL-6 receptor complex inhibits the proliferation of dermal fibroblasts. Int J Immunopharmacol 18:89–94PubMedCrossRefGoogle Scholar
  30. 30.
    Oh JW, Katz A, Harroch S, Eisenbach L, Revel M, Chebath J (1997) Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells. Oncogene 15:569–577PubMedCrossRefGoogle Scholar
  31. 31.
    Qiu Y, Ravi L, Kung HJ (1998) Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 393:83–85PubMedCrossRefGoogle Scholar
  32. 32.
    Mizoguchi H, Komiyama S, Matsui K, Hamanaka R, Ono M, Kiue A, Kobayashi M, Shimizu N, Welgus HG, Kuwano M (1991) The response to epidermal growth factor of human maxillary tumor cells in terms of tumor growth, invasion and expression of proteinase inhibitors. Int J Cancer 49:738–743PubMedCrossRefGoogle Scholar
  33. 33.
    Welch DR, Fabra A, Nakajima M (1990) Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 87:7678–76782PubMedCrossRefGoogle Scholar
  34. 34.
    Chambers SK, Wang Y, Gertz RE, Kacinski BM (1995) Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res 55:1578–1585PubMedGoogle Scholar
  35. 35.
    Noda I, Fujieda S, Ohtsubo T, Tsuzuki H, Tanaka N, Sunaga H, Saito H (1999) Granulocyte-colony-stimulating factor enhances invasive potential of human head-and-neck-carcinoma cell lines. Int J Cancer 80:78–84PubMedCrossRefGoogle Scholar
  36. 36.
    Obata NH, Tamakoshi K, Shibata K, Kikkawa F, Tomoda Y (1997) Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res 17:337–342PubMedGoogle Scholar
  37. 37.
    Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H, Herold-Mende C (2003) Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer 106:34–44PubMedCrossRefGoogle Scholar
  38. 38.
    Yao JS, Zhai W, Young WL, Yang GY (2006) Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: the role for KDR and MMP-9. Biochem Biophys Res Commun 342:1396–404PubMedCrossRefGoogle Scholar
  39. 39.
    Omori K, Naruishi K, Nishimura F, Yamada-Naruishi H, Takashiba S (2004) High glucose enhances interleukin-6-induced vascular endothelial growth factor 165 expression via activation of gp130-mediated p44/42 MAPK-CCAAT/enhancer binding protein signaling in gingival fibroblasts. J Biol Chem 279:6643–6649PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Takeharu Kanazawa
    • 1
  • Hiroshi Nishino
    • 2
  • Masahiro Hasegawa
    • 3
  • Yasushi Ohta
    • 1
  • Yukiko Iino
    • 1
  • Keiichi Ichimura
    • 2
  • Yutaka Noda
    • 3
  1. 1.Department of OtolaryngologyJichi Medical UniversityOmiya Saitama City, SaitamaJapan
  2. 2.Department of OtolaryngologyJichi Medical UniversityTochigiJapan
  3. 3.Department of Otolaryngology, Faculty of MedicineUniversity of the RyukyusNakagami, OkinawaJapan

Personalised recommendations